RESULTS	In the first trial , the natalizumab and placebo groups had similar rates of response ( 56 percent and 49 percent , respectively ; P = 0.05 ) and remission ( 37 percent and 30 percent , respectively ; P = 0.12 ) at 10 weeks .\